Yao Lin, Wang Guo-Lin, Shen Yuan, Wang Zhuang-Ye, Zhan Bing-Dong, Duan Li-Jun, Lu Bing, Shi Chao, Gao Yu-Meng, Peng Hong-Hong, Wang Guo-Qiang, Wang Dong-Mei, Jiang Ming-Dong, Cao Guo-Ping, Ma Mai-Juan
State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Beijing, China.
Wuxi Municipal Center for Disease Control and Prevention, Wuxi, China.
J Infect Dis. 2021 Aug 16;224(4):586-594. doi: 10.1093/infdis/jiab255.
The duration of humoral and T and B cell response after the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unclear.
We performed a cross-sectional study to assess the virus-specific antibody and memory T and B cell responses in coronavirus disease 2019 (COVID-19) patients up to 343 days after infection. Neutralizing antibodies and antibodies against the receptor-binding domain, spike, and nucleoprotein of SARS-CoV-2 were measured. Virus-specific memory T and B cell responses were analyzed.
We enrolled 59 patients with COVID-19, including 38 moderate, 16 mild, and 5 asymptomatic patients; 31 (52.5%) were men and 28 (47.5%) were women. The median age was 41 years (interquartile range, 30-55). The median day from symptom onset to enrollment was 317 days (range 257 to 343 days). We found that approximately 90% of patients still have detectable immunoglobulin (Ig)G antibodies against spike and nucleocapsid proteins and neutralizing antibodies against pseudovirus, whereas ~60% of patients had detectable IgG antibodies against receptor-binding domain and surrogate virus-neutralizing antibodies. The SARS-CoV-2-specific IgG+ memory B cell and interferon-γ-secreting T cell responses were detectable in more than 70% of patients.
Severe acute respiratory syndrome coronavirus 2-specific immune memory response persists in most patients approximately 1 year after infection, which provides a promising sign for prevention from reinfection and vaccination strategy.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染后体液免疫以及T细胞和B细胞反应的持续时间仍不清楚。
我们进行了一项横断面研究,以评估2019冠状病毒病(COVID-19)患者在感染后长达343天的病毒特异性抗体以及记忆T细胞和B细胞反应。检测了中和抗体以及针对SARS-CoV-2受体结合域、刺突蛋白和核蛋白的抗体。分析了病毒特异性记忆T细胞和B细胞反应。
我们纳入了59例COVID-19患者,其中包括38例中度患者、16例轻度患者和5例无症状患者;31例(52.5%)为男性,28例(47.5%)为女性。中位年龄为41岁(四分位间距,30 - 55岁)。从症状出现到入组的中位天数为317天(范围257至343天)。我们发现,约90%的患者仍可检测到针对刺突蛋白和核衣壳蛋白的免疫球蛋白(Ig)G抗体以及针对假病毒的中和抗体,而约60%的患者可检测到针对受体结合域的IgG抗体和替代病毒中和抗体。在超过70%的患者中可检测到SARS-CoV-2特异性IgG⁺记忆B细胞和分泌干扰素-γ的T细胞反应。
严重急性呼吸综合征冠状病毒2特异性免疫记忆反应在大多数患者感染后约1年持续存在,这为预防再次感染和疫苗接种策略提供了一个有希望的迹象。